Results overview: Found 1 records in 0.03 seconds.
Articles, 1 records found
Articles 1 records found  
1.
11 p, 2.0 MB Enhancement of Antiviral CD8 + T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab / Blanch-Lombarte, Oscar (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Gálvez, Cristina (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Revollo, Boris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Jiménez-Moyano, Esther (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Llibre, Josep M.. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Manzano, José Luís (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Boada, Aram (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Dalmau, Judith (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; E. Speiser, Daniel (University of Lausanne, Switzerland) ; Clotet Sala, Bonaventura (Universitat Autònoma de Barcelona. Departament de Medicina) ; G. Prado, Julia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background: Pembrolizumab is an immune checkpoint inhibitor against programmed cell death protein-1 (PD-1) approved for therapy in metastatic melanoma. PD-1 expression is associated with a diminished functionality in HIV-1 specific-CD8 + T cells. [...]
2019 - 10.3390/jcm8122089
Journal of clinical medicine, Vol. 8 (december 2019)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.